Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

12 months ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 Haematologica Spotlight 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

The study, led by Dr. Wang Jianxiang and his team,

evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

Patients achieving complete remission (CR)

after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia

1 year ago CAR-T

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.

🌟 CAR-T therapy, or Chimeric Antigen Receptor T-cell Immunotherapy, essentially involves reengineering a patient’s immune T cells outside the body to recognize antigens on the surface of tumor cells. These modified cells are then reintroduced into the patient, effectively identifying and eliminating cancer cells. Scientists have been tirelessly working to extend CAR-T therapy beyond blood cancers to various other types.

💡 Moreover, research from both clinical and preclinical studies indicates that CAR-T therapy holds great promise beyond cancer treatment. It shows potential applications in autoimmune diseases, chronic infections, heart diseases, aging-related conditions, and more.

🌐 In recent years, scientists have focused on applying CAR-T therapy to solid tumors, exploring its potential in cancer types beyond blood-related malignancies. Early research results suggest that the next frontier for CAR-T therapy may extend to various fields outside cancer, including autoimmune diseases (systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, type 1 diabetes, asthma), fibrotic diseases (fibrosis in the heart, liver, lungs, and kidneys), aging-related conditions (liver fibrosis, solid tumors, atherosclerosis, natural aging), and infectious diseases (HIV/AIDS, hepatitis B and C, pulmonary tuberculosis).

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

#immunotherapyrevolution #CARTTherapy #MedicalInnovation #BeyondCancer #ImmunotherapyRevolution #CART #cancer #tumor #cancertreatment #tcell

1 year ago CAR-T

Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai

🌈🌈Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai! 🌟🌟 #CARTVictory

⚡️⚡️Lyn, a mother of three from Singapore, faced unexpected health challenges in 2022. She experienced persistent pain in her shoulders, neck, and upper limbs, disrupting her sleep and even affecting her ability to breathe. A visit to the emergency department at Shanghai Jiahui International Hospital revealed a shocking discovery – a massive tumor in her mediastinum, measuring 15 cm in diameter! The compression from this large mass not only caused excruciating pain but also impacted nearby organs such as the heart, major blood vessels, and lungs, leading to Superior Vena Cava Syndrome (SVCS). Lyn struggled with breathing difficulties, posing an imminent threat to her life.

🌸🌸The diagnosis pointed to “Primary Mediastinal Large B-cell Lymphoma,” a relatively uncommon subtype of lymphoma, prevalent among young individuals, particularly females. Despite undergoing various comprehensive treatments, including chemotherapy combined with targeted therapy and consolidative radiotherapy, Lyn unfortunately showed no response to these treatments. Eventually, the decision was made to pursue CAR-T cell therapy.

🧶🧶Lyn’s husband emphasized, “The cost of CAR-T treatment abroad is significantly higher than in China, and the waiting period is at least 3-6 months. We trust the medical expertise of China and Shanghai Jiahui. Their professionalism and meticulous care left a deep impression on us. Our decision was absolutely correct.”

💥💥 The treatment team at Shanghai Jiahui International Hospital, led by Director Vicky H. Lee and Dr. Lili Zhou, the head of the Hematology and Oncology Department, developed a meticulous treatment plan to navigate Lyn through the entire CAR-T therapy. They highlighted the critical importance of two stages: the period from cell collection to pre-infusion and the phase post-infusion, which poses a risk of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

🍁🍁 After careful preliminary treatments, infection screening, and confirmation through cell collection, Lyn received the CAR-T cell infusion. Following infusion, the “T-cell soldiers” proliferated successfully in her body, providing relief from tumor-related pain. Upon clinical assessment confirming stable conditions, Lyn smoothly transitioned to being discharged.

⛵️⛵️ It’s worth noting that CAR-T therapy costs comprise drug and non-drug expenses, with the overall treatment expenses significantly lower in China compared to Western countries. Shanghai Jiahui International Hospital collaborates with local high-quality medical resources such as Ruijin Hospital and Tongji Hospital, offering patients a comprehensive one-stop CAR-T diagnostic and therapeutic service.

#CART #SurvivorStories #MedicalMiracle #Inspiration #JiahuiInternationalHospital #CancerSurvivor #CARTTherapy #HealthJourney #advancedmedicineinchina #chinesemedicine

1 year ago CAR-T

2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy

🌟2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy 🌏

LANCET

Dive into the cutting-edge world of CAR T-cell therapy, where China is making waves in the realm of cellular treatments. Since the inception of CAR T-cell clinical trials in 2013, this groundbreaking therapy has become a beacon of hope for cancer patients across the country.

🔬 Explosive Growth: By 2017, China led the globe in the number of CAR T-cell-related clinical trials, marking a pivotal moment in the evolution of cancer treatments. Fast forward to 2021, and Chinese cell therapy companies have amassed a staggering $237 million in funding, reflecting the robust expansion of CAR T-cell therapy in the nation.

🌐 Government Support: A deep dive into the research unveils the influential role of Chinese government policies in propelling CAR T-cell therapy forward. Strong governmental backing, coupled with capital influx, massive patient demand, and a unique healthcare system, lays the foundation for the accelerated growth of this revolutionary therapy in China.

🎗️ Overcoming Challenges: While CAR T-cell therapy is still in its infancy for solid tumors, it has achieved remarkable success in treating blood cancers. China has emerged as a global leader in conducting clinical trials, particularly focusing on hematologic malignancies like B-cell lymphomas. CAR-T cells, reprogrammed to combat cancer, offer a beacon of hope for those facing these formidable diseases.

🚀 Pushing Boundaries: Beyond blood cancers, Chinese researchers are actively exploring the potential of CAR-T cell therapy in various solid tumors. Preliminary studies hint at promising results for liver, pancreatic, and brain cancers. China’s commitment to medical innovation shines through as it pushes the boundaries of cancer research and treatment strategies.

🌈 Hope for the Future: Join us in celebrating the strides China is making in cancer research. Every breakthrough in CAR T-cell therapy brings us closer to a future where cancer is not just treated but conquered.

💪🏼🔬 #CARTCellChina #MedicalInnovation #CancerBreakthrough #HopeForTheFuture #GlobalHealthRevolution #CellTherapy #LANCET #HEMATOLOGY

1 year ago CAR-T

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🌞In a groundbreaking development, the Hematology Department at Peking Union Medical College Hospital has achieved remarkable treatment outcomes with commercial CAR-T therapy since 2021.

🌞Meet Mr. Li, a 59-year-old with a history of hypertension. In September 2019, he noticed swelling in his right elbow, which worsened over three months, prompting concerns. After visits to multiple hospitals, he was diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL). Further consultations revealed additional challenges: the presence of TP53 and MYD88 gene mutations, adding complexity to his case.

🌞Local hospitals initiated frontline treatments, utilizing drugs such as cyclophosphamide, prednisone, ibrutinib, and rituximab. While the initial treatment provided relief, it was short-lived. After six months of rest, Mr. Li experienced discomfort in his lower abdomen, leading to a subsequent diagnosis of DLBCL metastasis. Despite second, third, and fourth-line treatments at local hospitals, his condition remained uncontrolled.

🌞In December 2021, Mr. Li placed his last hope in the hands of the lymphoma team at Peking Union Medical College Hospital and underwent CAR-T therapy.

On December 27, 2021, the patient underwent a successful single-cell collection, followed by CAR-T cell infusion on January 20, 2022. Post-infusion, all indicators returned to normal, with only transient fever and CAR-T-related neutropenia observed. Targeted treatment promptly addressed these symptoms, leading to their resolution. One month after discharge, a complete response (CR) was achieved upon evaluation.

🌞Professor Wang Wei, drawing on clinical expertise, emphasized that:

TP53-mutated patients often exhibit limited response to conventional frontline treatments, making CAR-T therapy a potential benefit.

🌞For high-risk patients, especially those with dual expression and recurrence within 12 months, CAR-T therapy as a second-line treatment may yield benefits.

Post-CAR-T hematopoietic suppression, while common, requires nuanced management based on various factors. R-CHOP shows safety and efficacy in R/R DLBCL. Post-CAR-T bone marrow suppression is influenced by factors like prior chemotherapy lines, occurrence of CRS/ICANs, necessitating comprehensive clinical assessment and supportive care.

🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.

#CART #Success #LymphomaTreatment #MedicalAdvancements #pekingunion #Chinesecart

1 year ago CAR-T

Beacon of Hope in Cancer Treatment – What is the treatment process for CAR-T cell therapy?

Beacon of Hope in Cancer Treatment

😊😊😊 What is the treatment process for CAR-T cell therapy?

CAR-T cell therapy has emerged as a global miracle in cancer treatment, capturing widespread attention. By loading CAR onto T cells, these “super soldiers” can specifically identify and efficiently eliminate tumor cells, offering a fresh perspective for cancer patients.

Treatment Procedure:

💙Assessment: Doctors first evaluate whether the patient is suitable for CAR-T therapy, ensuring maximum benefit.

❤️Isolation and Sampling: T cells are extracted from peripheral blood, preparing for subsequent modifications.

💛Cell Modification: T cells are activated and modified in vitro, using biotechnological techniques to load the CAR structure for specific tumor cell recognition.

🧡Ex Vivo Expansion: Depending on the patient’s weight and treatment period, CAR-T cells are significantly expanded ex vivo to ensure an adequate quantity for treatment.

💚Infusion into the Body: The expanded CAR-T cells are reintroduced into the patient’s body, allowing the “super soldiers” to combat tumors.

💜Subsequent Monitoring: Close monitoring of the treatment’s effectiveness post CAR-T cell infusion, promptly addressing any adverse reactions to ensure optimal patient outcomes.

The advent of CAR-T cell therapy brings a new dawn for cancer patients, with its unique treatment mechanism and remarkable effects positioning it as a leader in the field of cancer immunotherapy. This scientific marvel is spreading hope globally, opening a gateway to recovery for cancer patients.

#CARTCellTherapy #CancerTreatment #HopeInScience #CART #Cancer #Whatiscancer #cancerpatient

1 year ago CAR-T

A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China

A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China

In a remarkable medical story, we turn our attention to the experiences of a friend seeking treatment in Hangzhou China. Tali, a well-known artist from Israel. In 2012, she was diagnosed with multiple myeloma, a malignant blood disease, and after seeking treatment in various European countries, including Israel and France, she found no definitive cure. In a moment of despair, she discovered a solution from Hangzhou, China, through the European Bone Marrow Transplant Association.

On October 6th, Tali and her family boarded a flight from Israel to Hangzhou. Under the meticulous care of Professor Huang He and his team at Zhejiang University’s First Hospital, Tali underwent over a month of intensive treatment. Today, Tali is finally on the road to recovery, expressing her gratitude to the medical staff through her preferred medium – art.

In the hospital room, Tali and Professor Huang He share laughs and conversations. The weather looks promising, initially being skeptical about her health when arriving in Hangzhou, encouragement from the medical team reignited her hope for recovery. Using her artistic language, she documented every moment of the treatment process.

After undergoing treatment, the excruciating bone pain gradually lessened, indicating a positive turn in her health.

“I can feel my body improving bit by bit. Green cells are gradually replacing the red ones, and my bone pain has completely disappeared. There are no tumor cells in the bone marrow anymore – they have vanished entirely.” Tali expressed.

The advanced treatment utilized at Zhejiang University’s First Hospital involves cutting-edge blood cell separation technology. Lymphocytes are extracted and genetically engineered to attack malignant tumor cells, successfully curing multiple myeloma. This revolutionary technique is known as CAR-T cell therapy. Zhejiang University’s First Hospital stands out as one of the earliest and most experienced clinical research centers using this technology, making it a pioneer in the field.

In here we bring you this inspiring story from Hangzhou, where art, science, and the human spirit come together in a tale of triumph over adversity.

#HangzhouMedicalMiracle #CARTCellTherapy #InspiringStories #MedicalAdvancements

1 year ago CAR-T

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

ALL- Acute Lymphoblastic Leukemia

The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.

Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL

Professor Ma Jun from the Harbin Institute of Hematology and Oncology shared notable progress in immunotherapy and cell treatment for Chinese ALL. Previously, the overall complete response (CR) rate for adult R/R ALL treatment in China was approximately 40%, with a mere 11% 3-year survival rate. The introduction of CAR-T cell therapy has been a paradigm shift, altering the long-term outcomes for R/R B-ALL patients.

Inaticabtagene Autoleucel demonstrates superior efficacy:

Higher overall response rates (ORR) at 3 months and beyond, with median duration of response (DOR) and overall survival (OS) surpassing other products.

Patients treated with Inaticabtagene Autoleucel exhibit similar long-term benefits in OS, whether or not they undergo subsequent transplantation.

Inaticabtagene Autoleucel boasts enhanced safety:

Lower incidence rates of grade 3 cytokine release syndrome (CRS), grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and infusion-related mortality compared to other CAR-T products.

Moreover, in minimal residual disease-positive (MRD+) B-ALL patients, CAR-T cell therapy has shown significant progress. It eradicates MRD, improves survival rates, and may serve as a first-line consolidation therapy for CR patients, aiding in:

Higher remission rates

Reduced transplant requirements, mitigating transplant-related complications

Maintenance of long-term remission for those unsuitable for allo-HSCT or unwilling to undergo it

Improved overall survival

Lower intensity and duration of intensive chemotherapy, leading to shorter treatment times and enhanced compliance.

The Future Outlook: Believing in the potential of CAR-T cell therapy, it is anticipated that this innovative treatment will extend hope to currently incurable diseases such as solid tumors and brain tumors. The strides made in Chinese medical innovation, exemplified by Inaticabtagene Autoleucel, signal a promising future for the global landscape of CAR-T cell therapy.

#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy #leukemia

1 year ago CAR-T

Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy

“Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy”

On January 5, 2024, the Fourth Chinese Hematology Development Conference was convened in Tianjin, China, concurrently hosting the CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS). The focus was directed towards the latest advancements and clinical applications of Inaticabtagene Autoleucel, presenting new pathways for standardized treatments.

Under the moderation of Professors Wu Depei and Hu Yu, Professor Wang Ying from the Institute of Hematology at the Chinese Academy of Medical Sciences presented a specialized lecture titled “Interpreting Key Clinical Data of Inaticabtagene Autoleucel.” Professor Wang highlighted the challenges faced by adult B-ALL patients in China, commonly treated with salvage chemotherapy ± hematopoietic stem cell transplantation. However, the median survival period is only 2-6 months, and targeted therapies yield a median survival of merely 7.7 months, necessitating an urgent need for more effective treatment methods. Recently, the Inaticabtagene Autoleucel infusion has been approved for treating adult R/R B-ALL patients.

Critical clinical research (NCT04684147) has revealed the substantial outcomes achieved with a single treatment of Inaticabtagene Autoleucel:

Rapid and profound remission: Within 3 months of treatment, the overall response rate (ORR) reached an impressive 82.1%, with a 100% negativity rate for minimal residual disease (MRD), showcasing the remarkable effects of Inaticabtagene Autoleucel within a short span.

Enduring remission: The 3-month post-treatment overall remission rate stood at 64.1%, with a 12-month sustained remission rate (DOR) of 80%. With a median follow-up of 8.0 months, the median relapse-free survival (RFS) period has not been reached. The one-year survival rates for overall infused patients, those achieving complete response (CR)/complete response with incomplete hematological recovery (CRi) within 3 months, and those reaching CR/CRi at 3 months were 67.9%, 72.0%, and 85.6%, respectively.

Good safety profile: The incidence rate of ≥3-grade cytokine release syndrome (CRS) was only 10.3%, and that of ≥3-grade immune effector cell-associated neurotoxicity syndrome (ICANS) was merely 7.7%. Moreover, patients recovered post-treatment without complications.

Furthermore, data from over 100 patients validated the clinical efficacy and safety of Inaticabtagene Autoleucel, affirming its robustness and offering renewed hope to a larger patient population. This breakthrough treatment provides a new avenue for tackling challenging diseases and is poised to revolutionize the landscape of hematologic cancer therapy.

1 year ago CAR-T

Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.

“Two Years of Complete Remission, CAR-T therapy has given her a new lease on life. She Thought the Journey Was Over”

Yun is a 78-year-old patient who achieved a continuous complete remission for two and a half years despite relapsed/refractory diffuse large B-cell lymphoma. Diagnosed in 2019, after enduring six rounds of chemotherapy, she initially achieved complete remission as confirmed by her healthcare team. Unfortunately, the period of remission was short-lived as Yun soon experienced disease relapse, and subsequent second-line treatments failed to yield positive results.

“I vividly remember when Director Wang Li encouraged me, mentioning an advanced method called Car-T, but it was quite expensive. I was hesitant, but I discussed it with my son when I got home. When my son and daughter-in-law heard about it, they insisted on treatment. My son said, ‘Mom, you’re the only mother I have in this world. As long as you’re here, our home is complete. Money can be earned again, and if the treatment isn’t successful, at least we won’t have regrets.’ I was deeply moved. At my age, I’ve already shown strength through previous treatments. I believe that wherever my health takes me is where I belong. Everyone’s support gave me a reason to stay strong again.”

In 2021, CAR-T cell therapy was approved and launched in China, and Yun underwent this treatment at Ruijin Hospital.

Dr. Wang Li, Director of Hematology at Ruijin Hospital, explained, “CAR-T cell therapy provides new treatment options for a wide range of cancer patients.”

“Before planning Yun’s CAR-T cell therapy, lymphoma experts, considering her current tumor status and medical history, anticipated potential adverse reactions during the treatment process and discussed handling protocols. Yun’s entire journey with CAR-T cell therapy was challenging. The medical team meticulously coordinated their efforts, successfully addressing adverse reactions after CAR-T treatment, ultimately averting potential risks.”

Despite lying in her hospital bed, Yun deeply appreciates the relentless dedication of her medical caregivers. “Sometimes, directors come to see me after 10 p.m., telling me they worked late but had to check on me; some arrive by my bedside as early as 7 a.m., concerned about my well-being. I continuously remind myself that I must strive, persist, and live up to the efforts made by doctors and my entire family,” said the 78-year-old Yun . “I made it through.”

#CARTCellSuccess #CancerWarrior #CompleteRemissionChronicles #FamilySupportMatters #CAR-TBreakthrough #InspiringHealthJourney #MedicalMiracles #NeverTooLateToFight #Cancerfight #Bloodcancer

#lymphoma

1 year ago CAR-T

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors

At this year’s ASH conference, Professor Huang He, the director of the First Affiliated Hospital of Zhejiang University School of Medicine, presented a significant study on CAR-T cell therapy for B-ALL, marking a groundbreaking stride in the treatment of malignant hematologic system tumors.

This study, targeting newly diagnosed adult Ph-positive acute lymphoblastic leukemia, investigated the combined treatment of dasatinib and CAR-T cell therapy as a frontline therapy for initial patients. The integration of CAR-T cell therapy with tyrosine kinase inhibitors (TKI) aimed to enhance treatment effectiveness.

The study revealed promising outcomes: among 18 patients, the complete molecular remission rate after CD19 CAR-T cell therapy reached 72.2%. Among these patients, subsequent treatment with CD22 CAR-T cells achieved a complete molecular remission rate of 76.9%. At a median follow-up of 13.5 months post CAR-T cell therapy, 16 patients maintained complete hematological remission, while 14 patients sustained complete molecular remission without undergoing allogeneic transplantation. Notably, no CRS (cytokine release syndrome) ≥ Grade 3 or ICANS (immune effector cell-associated neurotoxicity syndrome) occurred during CAR-T cell therapy.

Professor Huang He’s team’s groundbreaking research presented at the ASH conference signifies a leap forward in the treatment of blood-related cancers, signaling a more efficient and accessible era. These findings instill hope for refining treatment strategies and potentially making a significant impact in the field of hematologic oncology.

Beyond the groundbreaking progress in CAR-T cell therapy combined with TKI, the team showcased seven oral presentations and 26 poster exhibitions. These studies encompassed fundamental research on blood disorders, leukemia pathogenesis, acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma, myeloma, hematopoietic stem cell transplantation, and cellular immunotherapy, all crucial for enhancing clinical practices.

We eagerly anticipate further groundbreaking strides by Chinese research teams in cancer treatment studies, anticipating the transformative impact of these research findings in the future.

#ASHAnnualMeeting #HematologyResearch #CARTCellTherapy #StemCellTransplantation #BloodCancer #ClinicalInnovation #OncologyAdvancements #Cancertherapy #MedicalResearch #ASH #CART #CARTTherapy #CARTCell #TKI #tyrosinekinaseinhibitors

1 year ago CAR-T

Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML

A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.

The research involved 10 cases of CD7+ relapsed/refractory AML, where 30% of AML patients expressed CD7. Following treatment with NS7 CAR-T cell infusion, the results showed that within 4 weeks post-infusion, 70% of patients achieved complete bone marrow remission (CR), with 6 patients achieving a deep remission at the level of minimal residual disease (MRD). Notably, the loss of CD7 was identified as a primary reason for non-response in some patients.

The study also indicated that the majority of patients (80%) experienced mild cytokine release syndrome (CRS) post-infusion, with no observed neurotoxicity.

Furthermore, for select patients, continuing with a second allogeneic hematopoietic stem cell transplantation post NS7 CAR-T cell treatment resulted in promising long-term outcomes. However, further exploration is required for patients who did not undergo consolidative transplants to enhance treatment efficacy.

Professor Lu Peihua(Lu Daopei Hospital) remarked that this study highlights the potential of CD7 CAR-T cells as a bridging therapy before transplantation, demonstrating preliminary therapeutic efficacy for relapsed/refractory AML patients. Nevertheless, a comprehensive evaluation of its efficacy requires a larger sample size and longer-term follow-up.

This preliminary study represents a significant advancement in the field of AML treatment, but collaborative efforts and more research are still necessary. Looking ahead, we anticipate further studies and treatment outcomes to bring more beneficial therapeutic options for the long-term survival of patients, supported by a broader patient cohort and collaborative efforts from the medical community.

The outlook for this CD7 CAR-T cell therapy is promising, especially for AML patients who have undergone various treatments and allogeneic hematopoietic stem cell transplants. We look forward to more in-depth research and treatment outcomes in the future, offering more beneficial treatment choices for long-term survival among patients.

(source: ClinicalTrials.gov registration number NCT04938115

Preliminary results published by Professor Lu Peihua and their team in a top-tier journal)

#AMLResearch #CancerTreatment #CARTTherapy #Leukemia #MedicalBreakthrough #Cancer #AML #Immunotherapy #ClinicalTrials #BloodCancer #PatientCare #HealthcareAdvances #PrecisionMedicine #ScienceAndHealth #MedicalScience #CancerSurvivor #AMLWarriors #ResearchProgress #CancerFree #HopeInTreatment #acutemyeloidleukemia

Menu

Tags Archives: Blood Cancer

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 Haematologica Spotlight 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

The study, led by Dr. Wang Jianxiang and his team,

Patients achieving complete remission (CR)

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai

🌈🌈Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai! 🌟🌟 #CARTVictory

2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy

🌟2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy 🌏

Dive into the cutting-edge world of CAR T-cell therapy, where China is making waves in the realm of cellular treatments. Since the inception of CAR T-cell clinical trials in 2013, this groundbreaking therapy has become a beacon of hope for cancer patients across the country.

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.

Beacon of Hope in Cancer Treatment – What is the treatment process for CAR-T cell therapy?

Beacon of Hope in Cancer Treatment

😊😊😊 What is the treatment process for CAR-T cell therapy?

A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy

Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors

Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML

Recent Posts

Menu

Tags Archives: Blood Cancer

🔬 *Haematologica Spotlight* 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

The study, led by Dr. Wang Jianxiang and his team,

Patients achieving complete remission (CR)

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

🌈🌈Lyn’s Triumph Over Lymphoma: A CAR-T Journey in Shanghai! 🌟🌟 #CARTVictory

🌟2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy 🌏

Dive into the cutting-edge world of CAR T-cell therapy, where China is making waves in the realm of cellular treatments. Since the inception of CAR T-cell clinical trials in 2013, this groundbreaking therapy has become a beacon of hope for cancer patients across the country.

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.

Beacon of Hope in Cancer Treatment

😊😊😊 What is the treatment process for CAR-T cell therapy?

Recent Posts

🔬 Haematologica Spotlight 🔬